274 related articles for article (PubMed ID: 29523504)
1. Hepcidin agonists as therapeutic tools.
Casu C; Nemeth E; Rivella S
Blood; 2018 Apr; 131(16):1790-1794. PubMed ID: 29523504
[TBL] [Abstract][Full Text] [Related]
2. New thiazolidinones reduce iron overload in mouse models of hereditary hemochromatosis and β-thalassemia.
Liu J; Liu W; Liu Y; Miao Y; Guo Y; Song H; Wang F; Zhou H; Ganz T; Yan B; Liu S
Haematologica; 2019 Sep; 104(9):1768-1781. PubMed ID: 30792208
[TBL] [Abstract][Full Text] [Related]
3. Minihepcidin peptides as disease modifiers in mice affected by β-thalassemia and polycythemia vera.
Casu C; Oikonomidou PR; Chen H; Nandi V; Ginzburg Y; Prasad P; Fleming RE; Shah YM; Valore EV; Nemeth E; Ganz T; MacDonald B; Rivella S
Blood; 2016 Jul; 128(2):265-76. PubMed ID: 27154187
[TBL] [Abstract][Full Text] [Related]
4. A competitive enzyme-linked immunosorbent assay specific for murine hepcidin-1: correlation with hepatic mRNA expression in established and novel models of dysregulated iron homeostasis.
Gutschow P; Schmidt PJ; Han H; Ostland V; Bartnikas TB; Pettiglio MA; Herrera C; Butler JS; Nemeth E; Ganz T; Fleming MD; Westerman M
Haematologica; 2015 Feb; 100(2):167-77. PubMed ID: 25425686
[TBL] [Abstract][Full Text] [Related]
5. Liver iron concentrations and urinary hepcidin in beta-thalassemia.
Origa R; Galanello R; Ganz T; Giagu N; Maccioni L; Faa G; Nemeth E
Haematologica; 2007 May; 92(5):583-8. PubMed ID: 17488680
[TBL] [Abstract][Full Text] [Related]
6. Modulation of hepcidin as therapy for primary and secondary iron overload disorders: preclinical models and approaches.
Schmidt PJ; Fleming MD
Hematol Oncol Clin North Am; 2014 Apr; 28(2):387-401. PubMed ID: 24589273
[TBL] [Abstract][Full Text] [Related]
7. Hepcidin biology and therapeutic applications.
Nemeth E
Expert Rev Hematol; 2010 Apr; 3(2):153-5. PubMed ID: 21083458
[TBL] [Abstract][Full Text] [Related]
8. Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice.
Gardenghi S; Ramos P; Marongiu MF; Melchiori L; Breda L; Guy E; Muirhead K; Rao N; Roy CN; Andrews NC; Nemeth E; Follenzi A; An X; Mohandas N; Ginzburg Y; Rachmilewitz EA; Giardina PJ; Grady RW; Rivella S
J Clin Invest; 2010 Dec; 120(12):4466-77. PubMed ID: 21099112
[TBL] [Abstract][Full Text] [Related]
9. The pathophysiology and pharmacology of hepcidin.
Ruchala P; Nemeth E
Trends Pharmacol Sci; 2014 Mar; 35(3):155-61. PubMed ID: 24552640
[TBL] [Abstract][Full Text] [Related]
10. Hepcidin-induced hypoferremia is a critical host defense mechanism against the siderophilic bacterium Vibrio vulnificus.
Arezes J; Jung G; Gabayan V; Valore E; Ruchala P; Gulig PA; Ganz T; Nemeth E; Bulut Y
Cell Host Microbe; 2015 Jan; 17(1):47-57. PubMed ID: 25590758
[TBL] [Abstract][Full Text] [Related]
11. Hepcidin mimetics in polycythemia vera: resolving the irony of iron deficiency and erythrocytosis.
Handa S; Ginzburg Y; Hoffman R; Kremyanskaya M
Curr Opin Hematol; 2023 Mar; 30(2):45-52. PubMed ID: 36728649
[TBL] [Abstract][Full Text] [Related]
12. Hepcidin-ferroportin axis in health and disease.
Ginzburg YZ
Vitam Horm; 2019; 110():17-45. PubMed ID: 30798811
[TBL] [Abstract][Full Text] [Related]
13. β-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism.
Ginzburg Y; Rivella S
Blood; 2011 Oct; 118(16):4321-30. PubMed ID: 21768301
[TBL] [Abstract][Full Text] [Related]
14. Hemochromatosis: Evaluation of the dietary iron model and regulation of hepcidin.
Rishi G; Secondes ES; Nathan Subramaniam V
Biochim Biophys Acta Mol Basis Dis; 2018 Aug; 1864(8):2550-2556. PubMed ID: 29752985
[TBL] [Abstract][Full Text] [Related]
15. Small Molecule Inhibitors of NFkB Reverse Iron Overload and Hepcidin Deregulation in a Zebrafish Model for Hereditary Hemochromatosis Type 3.
Basu S; Jalodia K; Ranjan S; Yeh JJ; Peterson RT; Sachidanandan C
ACS Chem Biol; 2018 Aug; 13(8):2143-2152. PubMed ID: 29897731
[TBL] [Abstract][Full Text] [Related]
16. Oral ferroportin inhibitor ameliorates ineffective erythropoiesis in a model of β-thalassemia.
Manolova V; Nyffenegger N; Flace A; Altermatt P; Varol A; Doucerain C; Sundstrom H; Dürrenberger F
J Clin Invest; 2019 Dec; 130(1):491-506. PubMed ID: 31638596
[TBL] [Abstract][Full Text] [Related]
17. The role of hepcidin, GDF15, and mitoferrin-1 in iron metabolism of polycythemia vera and essential thrombocytosis patients.
Albayrak C; Tarkun P; Birtaş Ateşoğlu E; Eraldemir C; Özsoy ÖD; Terzi Demirsoy E; Mehtap Ö; Gedük A; Hacıhanefioğlu A
Turk J Med Sci; 2019 Feb; 49(1):74-80. PubMed ID: 30761871
[TBL] [Abstract][Full Text] [Related]
18. Hfe and Hjv exhibit overlapping functions for iron signaling to hepcidin.
Kent P; Wilkinson N; Constante M; Fillebeen C; Gkouvatsos K; Wagner J; Buffler M; Becker C; Schümann K; Santos MM; Pantopoulos K
J Mol Med (Berl); 2015 May; 93(5):489-98. PubMed ID: 25609138
[TBL] [Abstract][Full Text] [Related]
19. Differences in the erythropoiesis-hepcidin-iron store axis between hemoglobin H disease and β-thalassemia intermedia.
Origa R; Cazzola M; Mereu E; Danjou F; Barella S; Giagu N; Galanello R; Swinkels DW
Haematologica; 2015 May; 100(5):e169-71. PubMed ID: 25596269
[No Abstract] [Full Text] [Related]
20. Endogenous hepcidin and its agonist mediate resistance to selected infections by clearing non-transferrin-bound iron.
Stefanova D; Raychev A; Arezes J; Ruchala P; Gabayan V; Skurnik M; Dillon BJ; Horwitz MA; Ganz T; Bulut Y; Nemeth E
Blood; 2017 Jul; 130(3):245-257. PubMed ID: 28465342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
